Kura Oncology’s Promising Catalysts and Clinical Progress Justify Buy Rating
Mizuho Securities analyst Salim Syed has maintained their bullish stance on KURA stock, giving a Buy rating today. Salim Syed’s rating ...
kalkinemedia31m
Why Are Institutional Investors Eyeing Hemogenyx’s CAR-T Therapy...
Highlights,Hemogenyx Pharmaceuticals secures funding for phase I trials of its HEMO-CAR-T therapy.,The therapy focuses on ...
Armed robbery in Revesby1h
AML Drug Resistance Mapped at Single-Cell Level
In a recent publication of the acute myeloid leukemia (AML) arm of the Tumor Profiler, researchers demonstrated that multi-OMICS profiles can be generated in a clinically meaningful turnaround time ...
Hemogenyx Pharmaceuticals PLC Announces Institutional Investment
About Hemogenyx Pharmaceuticals plc Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and ...
TipRanks on MSN3h
Hemogenyx Pharmaceuticals Secures Funding for Clinical Trials
HemoGenyx Pharmaceuticals Plc (GB:HEMO) has released an update. Hemogenyx Pharmaceuticals has secured a £600,000 investment from an institutional ...
TipRanks on MSN3h
Syncona’s Autolus Gains FDA Approval for Leukemia Therapy
Syncona Shs GBP (GB:SYNC) has released an update. Syncona’s portfolio company, Autolus Therapeutics, has received FDA approval for AUCATZYL®, a ...
Iredell Free News9h
Pulling for Chris! Community rallies to help man battling cancer (Photo Gallery)
As word of his diagnosis spread, friends, neighbors, and even strangers wanted to help. A small committee of friends and ...